TAOX · Insider Trading
Tao Synergies Inc. Common Stock
Every open-market purchase and sale reported by TAOX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-19 | Robert Ephron | Director | A | +10,000 deriv. | — |
| 2026-05-19 | William S. Singer | Director | A | +35,000 deriv. | — |
| 2026-05-19 | Joshua Silverman | Executive Chairman | A | +200,000 deriv. | — |
| 2026-05-19 | Robert Weinstein | Chief Financial Officer | A | +30,000 deriv. | — |
| 2026-05-19 | Bruce Bernstein | Director | A | +55,000 deriv. | — |
| 2026-04-08 | Robert Ephron | Director | A | +800 deriv. | — |
| 2026-04-08 | William S. Singer | Director | A | +800 deriv. | — |
| 2026-04-08 | Bruce Bernstein | Director | A | +800 deriv. | — |
| 2025-10-17 | Robert Ephron | Director | MIXED | +4,500 | −$21.69K |
| 2025-10-17 | Joshua Silverman | Executive Chairman | MIXED | +60,000 | −$289.20K |
| 2025-10-17 | Jonathan Schechter | Director | A | +10,000 deriv. | — |
| 2025-10-17 | William S. Singer | Director | MIXED | +9,000 | −$43.38K |
| 2025-10-17 | Bruce Bernstein | Director | MIXED | +15,000 | −$72.30K |
| 2025-10-17 | Robert Weinstein | Chief Financial Officer | MIXED | +6,000 | −$28.92K |
| 2025-07-02 | Alan J Tuchman | Chief Medical Officer | MIXED | +2,589 | −$13.55K |
| 2025-07-02 | William S. Singer | Director | MIXED | +9,246 | −$48.39K |
| 2025-07-02 | Jonathan Schechter | Director | MIXED | +12,945 | −$67.75K |
| 2025-07-02 | Bruce Bernstein | Director | MIXED | +14,794 | −$77.42K |
| 2025-07-02 | Joshua Silverman | Executive Chairman | MIXED | +25,151 | −$131.63K |
| 2025-07-02 | Robert Weinstein | Chief Financial Officer | MIXED | +9,246 | −$48.39K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joshua Silverman | Executive Chairman | 126,681 | $344.57K |
| Bruce Bernstein | Director | 30,897 | $84.04K |
| William S. Singer | Director | 19,566 | $53.22K |
| Robert Weinstein | Chief Financial Officer | 16,574 | $45.08K |
| Jonathan Schechter | Director | 14,035 | $38.18K |
| Robert Ephron | Director | 7,500 | $20.40K |
| Alan J Tuchman | Chief Medical Officer | 3,909 | $10.63K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TAOX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.